Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Buy” at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February […]